Genome-wide/NN
Association/NN
Study/NN
Identified/JJ
TIMP2/NN
Genetic/JJ
Variant/JJ
with/IN
Susceptibility/NN
to/TO
Osteoarthritis/NN
./.
====================
Osteoarthritis/NN
(/(
OA/NN
)/)
is/VBZ
the/DT
most/JJS
common/JJ
degenerative/JJ
joint/NN
disorder/NN
in/IN
the/DT
elderly/JJ
population/NN
./.
====================
To/TO
identify/VB
OA-associated/JJ
genetic/JJ
variants/NNS
and/CC
candidate/NN
genes/NNS
,/,
we/PRP
conducted/VBD
a/DT
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
./.
====================
A/DT
total/JJ
3,793/CD
samples/NNS
(/(
476/CD
cases/NNS
:/:
wrist/NN
＋/CD
knee/JJ
and/CC
3317/CD
controls/NNS
)/)
from/IN
a/DT
community-based/JJ
epidemiological/JJ
study/NN
were/VBD
genotyped/VBN
using/VBG
the/DT
Affymetrix/JJ
SNP/NN
5.0/CD
./.
====================
An/DT
intronic/JJ
SNP/NN
(/(
rs4789934/NN
)/)
in/IN
the/DT
TIMP2/NN
(/(
tissue/NN
inhibitor/NN
of/IN
metalloproteinase-2/NN
)/)
showed/VBD
the/DT
most/JJS
significance/RB
with/IN
OA/NN
(/(
odd/JJ
ratio/NN
[/(
OR/NN
]/)
=/JJ
2.06/CD
,/,
95/CD
%/NN
confidence/NN
interval/JJ
[/(
CI/NN
]/)
=/JJ
1.52-2.81/CD
,/,
p/NN
=/JJ
4.01/CD
×/CD
10－6/CD
)/)
./.
====================
Furthermore/RB
,/,
a/DT
polymorphism/NN
(/(
rs1352677/NN
)/)
in/IN
the/DT
NKAIN2/NN
(/(
Na＋/K＋/NNP
transporting/VBG
ATPase/NN
interacting/VBG
2/CD
)/)
was/VBD
suggestively/RB
associated/VBN
with/IN
OA/NN
(/(
OR/NN
=/JJ
1.43/CD
,/,
CI/NN
=/JJ
1.22-1.66/CD
,/,
p/NN
=/JJ
7.01/CD
×/CD
10－6/CD
)/)
./.
====================
The/DT
present/JJ
study/NN
provides/VBZ
new/JJ
insights/NNS
into/IN
the/DT
identification/NN
of/IN
genetic/JJ
predisposing/VBG
factors/NNS
for/IN
OA/NN
./.
====================
Keywords/NNS
:/:
genome-wide/JJ
association/NN
study/NN
,/,
osteoarthritis/NN
,/,
polymorphism/NN
,/,
TIMP2Osteoarthritis/NN
(/(
OA/NN
)/)
is/VBZ
the/DT
most/JJS
common/JJ
joint/NN
disorder/NN
characterized/VBN
by/IN
progressive/JJ
cartilage/NN
loss/NN
,/,
and/CC
consequently/RB
increases/VBZ
serious/JJ
social/economic/JJ
problems/VBZ
in/IN
the/DT
elderly/JJ
population/NN
worldwide/NN
(/(
Du/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Ikegawa/NNP
,/,
2007/CD
)/)
./.
====================
As/IN
with/IN
any/DT
joint/NN
affected/VBN
by/IN
osteoarthritis/NN
,/,
the/DT
primary/JJ
symptom/JJ
for/IN
wrist/NN
and/CC
knee/JJ
OA/NN
as/IN
predominant/JJ
weightbearing/VBG
joints/NNS
is/VBZ
intractable/JJ
pain/NN
with/IN
increased/VBN
stiffness/RB
./.
====================
Specifically/RB
,/,
wrist/NN
OA/NN
can/MD
occurs/VBZ
secondary/JJ
to/TO
an/DT
intraarticular/JJ
fracture/NN
of/IN
the/DT
distal/JJ
radius/NN
or/CC
an/DT
extraarticular/JJ
fracture/NN
resulting/VBG
in/IN
malunion/NN
(/(
Weiss/NNP
and/CC
Rodner/NN
,/,
2007/CD
)/)
./.
====================
Several/JJ
risk/NN
factors/NNS
such/JJ
as/IN
age/NN
,/,
gender/NN
,/,
obesity/NN
,/,
and/CC
trauma/NN
have/VBP
been/VBN
confirmed/VBN
as/IN
environmental/JJ
confounding/VBG
factors/NNS
(/(
Haq/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
So/RB
far/RB
,/,
genetic/JJ
factors/NNS
contribute/VBP
to/TO
the/DT
risk/NN
of/IN
OA/NN
have/VBP
been/VBN
identified/VBN
through/IN
candidate/NN
gene/NN
approaches/NNS
(/(
Loughlin/NN
,/,
2002/CD
;/:
MacGregor/NN
and/CC
Spector/NN
,/,
1999/CD
)/)
./.
====================
However/RB
,/,
candidate/NN
genebased/VBN
studies/NNS
(/(
Miyamoto/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Mototani/NNP
et/FW
al./FW
,/,
2005/CD
;/:
RodriguezLopez/NNP
et/FW
al./FW
,/,
2008/CD
)/)
have/VBP
only/RB
a/DT
small/JJ
fraction/NN
of/IN
genetic/JJ
interactions/NNS
involved/VBN
in/IN
the/DT
pathogenesis/NN
,/,
and/CC
thereby/RB
provide/VBP
little/JJ
chance/NN
of/IN
discovering/VBG
novel/JJ
candidate/NN
genes/NNS
./.
====================
As/IN
a/DT
solution/NN
to/TO
the/DT
problem/NN
,/,
OA/NN
susceptibility/NN
genes/NNS
by/IN
recent/JJ
GWAS/NN
have/VBP
been/VBN
reported/VBN
across/IN
different/JJ
groups/NNS
(/(
Abel/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Dai/NNP
and/CC
Ikegawa/NN
,/,
2010/CD
;/:
Loughlin/NN
,/,
2002/CD
;/:
Spector/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
However/RB
,/,
most/JJS
of/IN
the/DT
previously/RB
reported/VBD
findings/NNS
have/VBP
produced/VBN
conflicting/VBG
results/NNS
with/IN
differential/JJ
genetic/JJ
effects/NNS
and/CC
limited/JJ
replication/NN
between/IN
ethnic/JJ
populations/NNS
./.
====================
(/(
Jiang/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Kerkhof/IN
et/FW
al./FW
,/,
2008/CD
;/:
Shi/NN
et/FW
al./FW
,/,
2008/CD
;/:
Snelling/JJ
et/FW
al./FW
,/,
2007/CD
;/:
Valdes/NNS
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
The/DT
ethnicspecific/JJ
variants/NNS
remain/VBP
to/TO
be/VB
identified/VBN
in/IN
East/JJ
Asian/JJ
population/NN
to/TO
overcome/VB
ethnic/JJ
difference/NN
and/CC
population/NN
structure/NN
./.
====================
We/PRP
therefore/RB
undertook/VBP
a/DT
genomewide/NN
association/NN
study/NN
to/TO
identify/VB
genetic/JJ
polymorphisms/NNS
influencing/VBG
OA/NN
./.
====================
The/DT
study/NN
samples/NNS
were/VBD
drawn/VBN
from/IN
the/DT
Korean/JJ
Genome/NN
and/CC
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
which/WDT
is/VBZ
an/DT
ongoing/JJ
prospective/JJ
communitybased/VBD
epidemiological/JJ
study/NN
in/IN
the/DT
communities/NNS
of/IN
Ansung/JJ
(/(
rural/JJ
)/)
and/CC
Ansan/NN
(/(
urban/JJ
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
Details/NNS
of/IN
the/DT
KoGES/NN
and/CC
the/DT
methods/NNS
are/VBP
described/VBN
in/IN
our/PRP$
previous/JJ
report/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
2006/CD
;/:
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Kim/NN
et/FW
al./FW
,/,
2005/CD
;/:
Lim/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
In/IN
brief/JJ
,/,
eligible/JJ
subjects/NNS
(/(
age/NN
4069/CD
years/NNS
)/)
were/VBD
examined/VBN
in/IN
20012002/CD
for/IN
demography/NN
and/CC
epidemiology/NN
and/CC
then/RB
follow/VBP
up/IN
biannually/RB
./.
====================
A/DT
total/JJ
of/IN
3,588/CD
men/NNS
and/CC
3,927/NN
women/NNS
agreed/RB
to/TO
participate/VB
in/IN
a/DT
baseline/NN
examination/NN
which/WDT
included/VBD
an/DT
interview/NN
,/,
blood/NN
tests/NNS
,/,
Xrays/NNS
,/,
and/CC
measurement/NN
of/IN
the/DT
body/NN
./.
====================
Informed/VBN
consents/NNS
were/VBD
obtained/VBN
from/IN
all/DT
of/IN
the/DT
participants/NNS
,/,
and/CC
Declaration/NN
of/IN
Helsinki/NN
for/IN
biomedical/JJ
research/NN
involving/VBG
human/JJ
subjects/NNS
was/VBD
also/RB
followed/VBN
./.
====================
The/DT
study/NN
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
the/DT
Korea/NN
Centers/NNS
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
./.
====================
X-rays/NNS
of/IN
both/DT
wrists/NNS
and/CC
knees/NNS
of/IN
subjects/NNS
were/VBD
taken/VBN
./.
====================
Radiographic/JJ
OA/NN
was/VBD
assessed/VBN
using/VBG
the/DT
Kellgren//NN
Lawrence/NN
(/(
K/L/NN
)/)
grading/JJ
system/NN
(/(
Kellgren/NN
and/CC
Lawrence/NN
,/,
1957/CD
)/)
./.
====================
Patients/NNS
with/IN
K/L/NN
grades/NNS
of/IN
2/CD
or/CC
higher/JJR
in/IN
wrists/NNS
or/CC
knees/NNS
were/VBD
diagnosed/VBN
with/IN
OA/NN
./.
====================
Among/IN
the/DT
7,515/CD
subjects/NNS
of/IN
the/DT
study/NN
,/,
3,793/CD
subjects/NNS
consented/VBD
to/TO
the/DT
X-ray/NN
examination/NN
./.
====================
Of/IN
these/DT
,/,
476/CD
patients/NNS
were/VBD
diagnosed/VBN
with/IN
OA/NN
(/(
387/CD
women/NNS
,/,
89/CD
men/NNS
,/,
median/JJ
age/NN
=/JJ
68/CD
years/NNS
[/(
range/NN
44-74/CD
]/)
)/)
,/,
and/CC
3,317/CD
subjects/NNS
were/VBD
classified/VBN
as/IN
normal/JJ
controls/NNS
(/(
women=1,773/NNS
,/,
men=1,544/NN
,/,
median/JJ
age/NN
=/JJ
57/CD
years/NNS
[/(
range/NN
43-74/CD
]/)
)/)
./.
====================
Genomic/JJ
DNA/NN
from/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
was/VBD
used/VBN
for/IN
this/DT
study/NN
./.
====================
We/PRP
performed/VBD
a/DT
pilot/NN
GWAS/NN
,/,
typing/NN
cases/NNS
and/CC
controls/VBZ
on/IN
a/DT
single/JJ
platform/NN
using/VBG
the/DT
Affymetrix/JJ
GenomeWide/NN
Human/JJ
SNP/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Genotype/NN
calls/NNS
were/VBD
determined/VBN
by/IN
Bayesian/JJ
Robust/NNP
Linear/JJ
Modeling/JJ
using/VBG
the/DT
Mahalanobis/NN
Distance/NN
algorithm/NN
(/(
Rabbee/NNP
and/CC
Speed/JJ
,/,
2006/CD
)/)
./.
====================
Details/NNS
of/IN
the/DT
genotyping/VBG
process/NN
are/VBP
presented/VBN
in/IN
our/PRP$
previous/JJ
report/NN
(/(
Cho/NN
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Of/IN
the/DT
SNPs/NNS
assayed/VBN
on/IN
the/DT
chip/NN
,/,
179,626/CD
SNPs/NNS
were/VBD
excluded/VBN
because/IN
they/PRP
showed/VBD
:/:
1/CD
)/)
a/DT
call/JJ
rate/NN
lower/JJR
than/IN
96.0/CD
%/NN
in/IN
cases/NNS
or/CC
controls/NNS
;/:
or/CC
2/CD
)/)
a/DT
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
＜/RB
1/CD
%/NN
in/IN
the/DT
population/NN
;/:
or/CC
3/CD
)/)
a/DT
significant/JJ
distortion/NN
from/IN
HardyWeinberg/JJ
equilibrium/NN
(/(
p/NN
＜/CD
0.05/CD
)/)
./.
====================
A/DT
total/JJ
of/IN
320,942/CD
SNPs/NNS
passed/VBN
all/DT
the/DT
quality/NN
control/NN
filters/NNS
(/(
mean/NN
call/JJ
rate/NN
98.0/CD
%/NN
)/)
./.
====================
To/TO
identify/VB
the/DT
effect/NN
of/IN
population/NN
stratification/NN
,/,
the/DT
genomic/JJ
inflation/NN
factor/NN
(/(
λ/LS
)/)
(/(
Clayton/NN
et/FW
al./FW
,/,
2005/CD
)/)
was/VBD
calculated/VBN
for/IN
all/DT
individuals/NNS
./.
====================
The/DT
two/CD
study/NN
cohorts/VBZ
(/(
Ansung/JJ
and/CC
Ansan/NN
)/)
have/VBP
shown/VBN
very/RB
similar/JJ
MAFs/NNS
for/IN
the/DT
SNPs/NNS
on/IN
the/DT
array/NN
,/,
and/CC
quantile-quantile/RB
(/(
Q-Q/NN
)/)
analysis/NN
for/IN
the/DT
comparison/NN
of/IN
genotype/JJ
frequencies/NNS
in/IN
both/DT
cohorts/NNS
confirmed/VBD
the/DT
genetic/JJ
homogeneity/NN
of/IN
these/DT
two/CD
components/NNS
of/IN
the/DT
KoGES/NN
study/NN
population/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
The/DT
allele/NN
frequencies/NNS
in/IN
OA/NN
cases/NNS
were/VBD
compared/VBN
to/TO
those/DT
in/IN
controls/NNS
using/VBG
the/DT
Chi-square/JJ
test/NN
and/CC
logistic/JJ
regression/NN
analysis/NN
./.
====================
The/DT
associations/NNS
between/IN
the/DT
case/NN
control/NN
status/NN
and/CC
each/DT
individual/JJ
SNP/NN
were/VBD
measured/VBN
by/IN
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
./.
====================
Covariates/NNS
used/VBN
for/IN
multivariable-adjustment/JJ
were/VBD
age/NN
,/,
sex/NN
,/,
and/CC
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
because/IN
these/DT
variables/NNS
were/VBD
significantly/RB
associated/VBN
with/IN
OA/NN
in/IN
our/PRP$
cohort/NN
./.
====================
Pair-wise/NN
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
among/IN
the/DT
polymorphisms/NNS
was/VBD
determined/VBN
by/IN
the/DT
expectation/NN
maximization/NN
algorithm/NN
./.
====================
When/WRB
determining/VBG
LD/NN
between/IN
SNPs/NNS
,/,
we/PRP
used/VBD
either/CC
of/IN
two/CD
measures/NNS
of/IN
LD/NN
:/:
an/DT
r2/NN
value/NN
≥/CD
0.8/CD
or/CC
a/DT
disequilibrium/NN
coefficient/JJ
(/(
D/NN
’/CD
)/)
≥/CD
0.95/CD
./.
====================
PLINK/NN
software/JJ
program/NN
(/(
http/NN
:/:
//pngu/FW
./.
====================
mgh/IN
./.
====================
harvard/RB
./.
====================
edu//RB
~purcell/plink//JJ
)/)
,/,
Haploview/NN
program/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
broad/JJ
./.
====================
mit/VBP
./.
====================
edu/mpg/haploview/NN
)/)
,/,
and/CC
SAS/NN
program/NN
(/(
version/NN
9.1/CD
;/:
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
were/VBD
used/VBN
for/IN
statistical/JJ
analysis/NN
./.
====================
The/DT
Q-Q/NN
plot/NN
indicated/VBD
lack/NN
of/IN
inflation/NN
due/JJ
to/TO
stratification/NN
,/,
and/CC
no/DT
differences/NNS
between/IN
case/NN
and/CC
control/NN
populations/NNS
were/VBD
detected/VBN
./.
====================
The/DT
estimated/VBN
genomic/JJ
control/NN
inflation/NN
factor/NN
(/(
λ/LS
)/)
was/VBD
1.009/CD
,/,
indicating/VBG
limited/JJ
evidence/NN
of/IN
population/NN
stratification/NN
in/IN
the/DT
KARE/NN
study/NN
samples/NNS
-/:
are/VBP
described/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
Table/JJ
2/CD
lists/NNS
the/DT
most/JJS
significant/JJ
genetic/JJ
variants/NNS
from/IN
GWAS/NN
analysis/NN
./.
====================
We/PRP
identified/VBD
two/CD
intronic/JJ
SNPs/NNS
with/IN
Pvalues/NNS
＜/CD
1×10－5/CD
./.
====================
A/DT
SNP/NN
(/(
rs4789934/NN
)/)
in/IN
the/DT
TIMP2/NN
(/(
tissue/NN
inhibitor/NN
of/IN
metalloproteinase2/NN
)/)
gene/NN
showed/VBD
the/DT
most/JJS
significant/JJ
association/NN
with/IN
OA/NN
./.
====================
The/DT
adjusted/JJ
ORs/NNS
were/VBD
2.06/CD
(/(
95/CD
%/NN
confidence/NN
interval/JJ
(/(
CI/NN
)/)
=/JJ
1.522.81/CD
)/)
,/,
and/CC
the/DT
adjusted/JJ
Pvalues/NNS
were/VBD
4.01×10－6/CD
./.
====================
In/IN
addition/NN
,/,
our/PRP$
study/NN
also/RB
identified/VBD
suggestive/JJ
association/NN
in/IN
the/DT
NKAIN2/NN
(/(
Na＋/K＋/NN
transporting/VBG
ATPase/NN
interacting/VBG
2/CD
)/)
(/(
OR/NN
=/JJ
1.43/CD
,/,
CI/NN
=/JJ
1.221.66/CD
,/,
p/NN
=/JJ
7.01×10－6/CD
)/)
./.
====================
To/TO
support/VB
the/DT
biological/JJ
relevance/NN
in/IN
silico/NN
,/,
we/PRP
provide/VBP
graphically/RB
summarized/VBD
information/NN
on/IN
preliminary/JJ
association/NN
by/IN
confidence/NN
values/NNS
of/IN
textual/JJ
evidence/NN
(/(
Fig/NN
./.
====================
1/CD
./.
====================
D/NN
)/)
./.
====================
Nodes/NNS
represent/VBP
biological/JJ
entities/NNS
with/IN
different/JJ
colors/NNS
for/IN
different/JJ
classes/NNS
./.
====================
Edges/NNS
represent/VBP
strong/JJ
associations/NNS
between/IN
two/CD
entities/VBZ
(/(
i./FW
e./FW
,/,
TIMP2/NN
effects/NNS
to/TO
tissue/NN
inhibition/NN
,/,
and/CC
functional/JJ
interactions/NNS
with/IN
TIMP4/NN
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
two/CD
novel/JJ
polymorphisms/NNS
associated/VBN
with/IN
OA/NN
./.
====================
Intronic/JJ
SNPs/NNS
,/,
rs4789934/NN
in/IN
TIMP2/NN
and/CC
rs1352677/NN
in/IN
NKAIN2/NN
,/,
showed/VBD
significant/JJ
associations/NNS
with/IN
OA/NN
./.
====================
To/TO
date/NN
,/,
OA/NN
susceptibility/NN
genes/NNS
from/IN
genomewide/NN
association/NN
studies/NNS
have/VBP
been/VBN
reported/VBN
primarily/RB
in/IN
samples/NNS
of/IN
European/JJ
descent/JJ
./.
====================
The/DT
function/NN
of/IN
TIMP2/NN
is/VBZ
inhibition/NN
of/IN
MMP/NN
./.
====================
Osteoarthritic/JJ
cartilage/NN
is/VBZ
characterized/VBN
by/IN
the/DT
imbalance/NN
between/IN
MMPs/NNS
and/CC
TIMPs/NNS
./.
====================
The/DT
level/NN
of/IN
lytic/JJ
enzymes/NNS
such/JJ
as/IN
MMP1/NN
,/,
MMP3/NN
,/,
and/CC
MMP13/NN
was/VBD
increased/VBN
,/,
and/CC
the/DT
level/NN
of/IN
TIMP1/NN
was/VBD
decreased/VBN
in/IN
OA/NN
cartilage/JJ
(/(
Krane/JJ
and/CC
Inada/NN
,/,
2008/CD
;/:
MartelPelletier/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
With/IN
the/DT
decreasing/VBG
level/NN
of/IN
TIMP/NN
,/,
MMP/NN
activity/NN
increases/VBZ
and/CC
leads/VBZ
to/TO
further/RBR
destruction/NN
of/IN
cartilage/JJ
,/,
the/DT
key/JJ
process/NN
in/IN
OA/NN
(/(
Cawston/NN
,/,
1998/CD
;/:
Krane/JJ
and/CC
Inada/NN
,/,
2008/CD
)/)
./.
====================
Estrogen/NN
may/MD
regulate/VB
the/DT
balance/NN
between/IN
MMP/NN
and/CC
TIMP/NN
activity/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2003/CD
)/)
,/,
which/WDT
would/MD
explain/VB
the/DT
gender/NN
and/CC
menopausal/JJ
correlations/NNS
with/IN
OA/NN
./.
====================
Although/IN
prior/JJ
reports/NNS
focused/VBD
primarily/RB
on/IN
TIMP1/NN
,/,
levels/NNS
of/IN
TIMP2/NN
,/,
a/DT
member/NN
of/IN
the/DT
same/JJ
gene/NN
family/NN
,/,
have/VBP
also/RB
been/VBN
shown/VBN
to/TO
increase/VB
in/IN
osteoarthritic/JJ
cartilage/NN
(/(
MartelPelletier/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
Lee/NNP
et/FW
al/JJ
./.
====================
./.
====================
reported/VBN
that/IN
TIMP4/NN
polymorphism/NN
(/(
rs17035945/NN
)/)
was/VBD
associated/VBN
with/IN
the/DT
risk/NN
of/IN
OA/NN
in/IN
the/DT
Korean/JJ
population/NN
as/IN
a/DT
result/NN
of/IN
altering/VBG
the/DT
folding/JJ
of/IN
the/DT
mRNA/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
The/DT
Na＋/K＋/JJ
ATPase/NN
is/VBZ
an/DT
important/JJ
regulator/NN
of/IN
ion/NN
homeostasis/NN
in/IN
many/JJ
cell/NN
types/NNS
(/(
Mobasheri/NNP
et/FW
al./FW
,/,
2000/CD
)/)
,/,
but/CC
its/PRP$
role/NN
in/IN
OA/NN
is/VBZ
not/RB
clear/JJ
./.
====================
In/IN
osteoblasts/NNS
,/,
which/WDT
synthesize/VBP
collagen/NN
and/CC
other/JJ
extracellular/JJ
matrix/NN
(/(
ECM/NN
)/)
components/NNS
,/,
the/DT
Na＋/K＋/NN
ATPase/NN
appears/VBZ
to/TO
maintain/VB
the/DT
transmembrane/JJ
gradient/NN
of/IN
Na＋/JJ
that/DT
drives/VBZ
intracellular/JJ
calcium/NN
homeostasis/NN
and/CC
ECM/NN
calcification/NN
(/(
Francis/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Hence/RB
,/,
the/DT
role/NN
of/IN
NKAIN2/NN
in/IN
the/DT
pathogenesis/NN
of/IN
OA/NN
may/MD
be/VB
related/JJ
to/TO
control/VB
of/IN
mineralization/NN
and/CC
maintenance/NN
of/IN
the/DT
ECM/NN
./.
====================
However/RB
,/,
the/DT
Na＋//JJ
K＋/NN
ATPase/NN
is/VBZ
expressed/VBN
in/IN
diverse/JJ
cell/NN
types/NNS
in/IN
the/DT
human/JJ
body/NN
and/CC
is/VBZ
not/RB
specific/JJ
to/TO
OA/NN
./.
====================
The/DT
detailed/JJ
contributions/NNS
of/IN
the/DT
Na＋/K＋/NN
ATPase/NN
to/TO
the/DT
pathogenesis/NN
of/IN
OA/NN
should/MD
be/VB
clarified/VBN
in/IN
further/JJ
investigations/NNS
./.
====================
The/DT
genetic/JJ
susceptibility/NN
to/TO
OA/NN
is/VBZ
likely/JJ
to/TO
vary/VB
for/IN
different/JJ
joint/NN
sites/NNS
(/(
Peach/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
The/DT
criteria/NNS
used/VBN
to/TO
diagnose/VB
OA/NN
also/RB
differ/VBP
among/IN
studies/NNS
and/CC
may/MD
explain/VB
conflicting/VBG
information/NN
./.
====================
Some/DT
studies/NNS
used/VBD
clinical/JJ
diagnosis/NN
while/IN
other/JJ
studies/NNS
using/VBG
X-ray/NN
and/CC
K/L/NN
grades/NNS
(/(
Kerkhof/NN
et/FW
al./FW
,/,
2008/CD
;/:
Miyamoto/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Spector/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
The/DT
present/JJ
study/NN
contains/VBZ
some/DT
limitations/NNS
./.
====================
No/DT
SNPs/NNS
met/NN
conventional/JJ
genome-wide/NN
significance/NN
level/NN
of/IN
＜/NN
5/CD
×/NN
10－8/CD
,/,
and/CC
no/DT
replication/NN
./.
====================
However/RB
it/PRP
would/MD
be/VB
interesting/JJ
to/TO
use/VB
the/DT
data/NNS
available/JJ
to/TO
perform/VB
meta-analysis/NN
or/CC
SNP/NN
lookup/NN
from/IN
a/DT
large/JJ
international/JJ
consortium/NN
in/IN
future/JJ
studies/NNS
to/TO
evaluate/VB
the/DT
significance/NN
of/IN
our/PRP$
results/NNS
./.
====================
In/IN
an/DT
attempt/NN
to/TO
address/VB
function/NN
prediction/NN
of/IN
SNP/NN
allele/NN
,/,
we/PRP
conducted/VBD
in/IN
silico/NN
functional/JJ
investigation/NN
to/TO
an/DT
uncharacterized/JJ
sequence/NN
variant/JJ
(/(
Yuan/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
The/DT
lead/NN
SNP/NN
(/(
rs4789934/NN
)/)
was/VBD
a/DT
predicted/VBN
functional/JJ
cofactor/NN
,/,
affecting/VBG
transcription/NN
factor/NN
binding/NN
sites/NNS
in/IN
the/DT
intronic/JJ
enhancer/NN
region/NN
./.
====================
This/DT
result/NN
was/VBD
further/RBR
associated/VBN
with/IN
functional/JJ
connectivity/NN
derived/VBN
from/IN
bioinformative/JJ
approaches/NNS
(/(
Lee/NNP
and/CC
Shatkay/NN
,/,
2009/CD
;/:
Szklarczyk/NN
et/FW
al/JJ
./.
====================
)/)
./.
====================
Therefore/RB
,/,
this/DT
concordance/NN
of/IN
the/DT
functional/JJ
evidence/NN
with/IN
the/DT
previous/JJ
studies/NNS
suggests/VBZ
an/DT
encouraging/VBG
sign/NN
of/IN
the/DT
results/NNS
in/IN
our/PRP$
GWAS/NN
./.
====================
However/RB
,/,
the/DT
biological/JJ
relevance/NN
of/IN
literature-derived/JJ
targets/NNS
needs/VBZ
to/TO
be/VB
fully/RB
validated/VBN
with/IN
experimental/JJ
tests/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
suggest/VBP
that/IN
a/DT
novel/JJ
polymorphism/NN
(/(
rs4789934/NN
)/)
in/IN
TIMP2/NN
was/VBD
associated/VBN
with/IN
OA/NN
./.
====================
Follow/IN
up/IN
studies/NNS
performed/VBN
with/IN
multiple/JJ
ethnic/JJ
populations/NNS
or/CC
larger/JJR
sample/NN
are/VBP
needed/VBN
before/IN
the/DT
effect/NN
of/IN
the/DT
variant/JJ
can/MD
be/VB
fully/RB
and/CC
accurately/RB
evaluated/VBD
./.
====================
We/PRP
anticipate/VBP
that/DT
identification/NN
of/IN
the/DT
causal/JJ
variants/NNS
through/IN
deep/JJ
sequencing/NN
and/CC
their/PRP$
functional/JJ
consequences/NNS
will/MD
lead/VB
to/TO
a/DT
better/RBR
understanding/NN
of/IN
the/DT
pathogenesis/NN
of/IN
OA/NN
./.
====================
